154 related articles for article (PubMed ID: 36008689)
1. Tissue immunostaining of candidate prognostic proteins in metastatic and non-metastatic prostate cancer.
Pereira ÉR; Pinheiro LCL; Francelino AL; Miqueloto CA; Guembarovski AFML; de Oliveira KB; Fuganti PE; de Syllos Cólus IM; Guembarovski RL
J Cancer Res Clin Oncol; 2023 Feb; 149(2):567-577. PubMed ID: 36008689
[TBL] [Abstract][Full Text] [Related]
2. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
3. Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN.
Sharma P; Knowell AE; Chinaranagari S; Komaragiri S; Nagappan P; Patel D; Havrda MC; Chaudhary J
Mol Cancer; 2013 Jun; 12():67. PubMed ID: 23786676
[TBL] [Abstract][Full Text] [Related]
4. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.
Aslan G; Irer B; Tuna B; Yorukoglu K; Saatcioglu F; Celebi I
Pathol Res Pract; 2006; 202(2):93-8. PubMed ID: 16413692
[TBL] [Abstract][Full Text] [Related]
5. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of NKX 3.1 and HOXB 13 in bone metastases originating from prostatic carcinoma among the Egyptian males.
Abouhashem NS; Salah S
Pathol Res Pract; 2020 Oct; 216(10):153221. PubMed ID: 32979741
[TBL] [Abstract][Full Text] [Related]
7. Utility of NKX3.1 Immunostaining in the Detection of Metastatic Prostatic Carcinoma on Fine-Needle Aspiration Smears.
Gan Q; Joseph CT; Guo M; Zhang M; Sun X; Gong Y
Am J Clin Pathol; 2019 Sep; 152(4):495-501. PubMed ID: 31175351
[TBL] [Abstract][Full Text] [Related]
8. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.
Lei Q; Jiao J; Xin L; Chang CJ; Wang S; Gao J; Gleave ME; Witte ON; Liu X; Wu H
Cancer Cell; 2006 May; 9(5):367-78. PubMed ID: 16697957
[TBL] [Abstract][Full Text] [Related]
9. Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma.
Jia L; Jiang Y; Michael CW
Diagn Cytopathol; 2017 Nov; 45(11):998-1004. PubMed ID: 28888085
[TBL] [Abstract][Full Text] [Related]
10. Expression of NKX3.1 in normal and malignant tissues.
Gelmann EP; Bowen C; Bubendorf L
Prostate; 2003 May; 55(2):111-7. PubMed ID: 12661036
[TBL] [Abstract][Full Text] [Related]
11. NKX3.1 Expression in Non-Prostatic Tumors and Characterizing its Expression in Esophageal/Gastroesophageal Adenocarcinoma.
Mehreen A; Manjee KG; Paralkar D; Paner GP; Lan T
Adv Anat Pathol; 2024 May; 31(3):202-205. PubMed ID: 38525603
[TBL] [Abstract][Full Text] [Related]
12. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
13. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.
Iwata T; Schultz D; Hicks J; Hubbard GK; Mutton LN; Lotan TL; Bethel C; Lotz MT; Yegnasubramanian S; Nelson WG; Dang CV; Xu M; Anele U; Koh CM; Bieberich CJ; De Marzo AM
PLoS One; 2010 Feb; 5(2):e9427. PubMed ID: 20195545
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
[TBL] [Abstract][Full Text] [Related]
15. Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression.
Vinall RL; Chen JQ; Hubbard NE; Sulaimon SS; Shen MM; Devere White RW; Borowsky AD
Dis Model Mech; 2012 Nov; 5(6):914-20. PubMed ID: 22563073
[TBL] [Abstract][Full Text] [Related]
16. TNFα-mediated loss of β-catenin/E-cadherin association and subsequent increase in cell migration is partially restored by NKX3.1 expression in prostate cells.
Debelec-Butuner B; Alapinar C; Ertunc N; Gonen-Korkmaz C; Yörükoğlu K; Korkmaz KS
PLoS One; 2014; 9(10):e109868. PubMed ID: 25360740
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma.
Takada N; Nishida H; Oyama Y; Kusaba T; Kadowaki H; Arakane M; Wada J; Urabe S; Daa T
Pathobiology; 2020; 87(1):30-36. PubMed ID: 31865345
[TBL] [Abstract][Full Text] [Related]
18. Polymorphic variants of the CASP3, CASP9, BCL-2 and NKX3-1 genes as candidate markers for prostate cancer susceptibility and poor prognosis.
de Souza MR; de Souza MF; de Nóbrega M; Cilião HL; Dos Reis MB; Fuganti PE; Cólus IMS
Mol Biol Rep; 2022 Sep; 49(9):9079-9087. PubMed ID: 35708863
[TBL] [Abstract][Full Text] [Related]
19. Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression.
Bowen C; Ostrowski MC; Leone G; Gelmann EP
Cancer Res; 2019 Aug; 79(16):4124-4134. PubMed ID: 31213464
[No Abstract] [Full Text] [Related]
20. Alterations of C-MYC, NKX3.1, and E-cadherin expression in canine prostate carcinogenesis.
Fonseca-Alves CE; Rodrigues MM; de Moura VM; Rogatto SR; Laufer-Amorim R
Microsc Res Tech; 2013 Dec; 76(12):1250-6. PubMed ID: 24030851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
